AI Engine
running...
━━ Actual  

━━ Predicted  

━━ Forecast
The above chart is predicting the stock Zymeworks Inc. - ZYME using Artifical Intelligence (AI) and Machine Learning (ML)
Privacy policy and disclaimers
How to read the charts
Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

352

Address:

Zymeworks Inc.
1385 West 8th Avenue
Suite 540
Vancouver BC V6H 3V9
Canada

Website:

http://www.zymeworks.com

Phone:

604-678-1388

Leave a comment

Your email address will not be published. Required fields are marked *